Special Issue "Targeting of Tumor Dormancy Pathway"
A special issue of Onco (ISSN 2673-7523).
Deadline for manuscript submissions: 31 December 2023 | Viewed by 180
Interests: DNA polymorphisms; RNA; miRNAs; carcinogenesis; bioinformatics; DNA damage; cell cycle; cancer
Interests: cancer immunology; cancer immunotherapy; biomarkers; precision oncology; immune resistance; cancer vaccines; immune escape; immune checkpoint inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue in Cancers: Biomarkers in the Era of Precision Oncology
Special Issue in Cancers: Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?
Special Issue in International Journal of Molecular Sciences: Research Progress in Molecular and Cellular Therapy of Cancer
Special Issue in Cancers: The Portrait of Cancer Immunotherapy: Tumor Microenvironment, Biomarkers and Immune Resistance—Volume II
Special Issue in Cancers: Discovery, Development and Application of Innovative Approaches to Cancer Therapy
Special Issue in Onco: Progress in Vaccination against Cancer - 2023 (PIVAC-23)
Special Issue in Onco: The Evolving Landscape of Contemporary Cancer Therapies
Special Issue in Cancers: Microbiomes and Modulation of Therapeutic Responses in Cancer
Dormant tumor cells, also known as minimal residual disease, represent a population of cancer cells that have entered a state of growth arrest, typically after primary tumor removal or during periods of remission. This dormant state allows them to evade conventional cancer therapies, such as chemotherapy or radiation, which primarily target actively dividing cells. It is generally thought that dormant tumor cells have the potential to reactivate and give rise to metastatic tumors years or even decades after initial treatment. However, from another perspective, keeping tumor cells silent for decades can be regarded as tantamount to cure. From both perspectives, it is important to understand the mechanisms underlying dormancy. Keeping tumor cells dormant for indefinite periods of time could form a new strategy of cancer treatment. This Special Issue will highlight the current state of the knowledge in tumor dormancy, targeting of tumor dormancy pathways, and future prospects for exploiting tumor dormancy for cancer therapies.
Dr. Athanassios Kotsinas
Dr. Constantin N. Baxevanis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Onco is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- dormant tumor cells
- conventional cancer therapies
- cancer therapies
- tumor dormancy
- targeting of tumor dormancy pathways